SRGA.Q Stock Overview Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Add noteSurgalign Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Surgalign Holdings Historical stock prices Current Share Price US$0.018 52 Week High US$4.00 52 Week Low US$0.005 Beta 1.49 1 Month Change 63.64% 3 Month Change -80.00% 1 Year Change -99.50% 3 Year Change -99.97% 5 Year Change -99.99% Change since IPO -100.00%
Recent News & Updates
Surgalign Holdings, Inc. Files Form 15 Nov 14
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index Jun 23 Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Surgalign Holdings, Inc. Filed for Bankruptcy Jun 20
See more updates
Surgalign Holdings, Inc. Files Form 15 Nov 14
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index Jun 23 Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Surgalign Holdings, Inc. Filed for Bankruptcy Jun 20
Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares Jun 12
Price target decreased by 19% to US$2.22 May 18
Consensus estimates of losses per share improve by 87% May 18
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research May 09
Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Consensus revenue estimates fall by 38% Apr 06
Full year 2022 earnings: EPS misses analyst expectations Apr 01
Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System Dec 16 Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million. Nov 17
Price target decreased to US$5.00 Nov 17
Consensus EPS estimates fall by 14% Nov 09
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 04
Price target decreased to US$11.00 Nov 03
Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022 Nov 03
Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 26
Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures Sep 27
Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System Sep 16
Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform Aug 25
Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system Aug 24 Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022
Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue Aug 09
Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary Aug 05
Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission Aug 04
Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 02
Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio Jul 07
Chief Financial Officer recently bought US$100k worth of stock May 20
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 12
Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022 May 12
Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System May 06
Price target decreased to US$1.00 Apr 27
Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022 Apr 12
Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022 Apr 08
Consensus forecasts updated Mar 22
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 18 Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer Mar 10
Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System Jan 19
Surgalign Holdings - A Future Of Digital Surgery Dec 21
Price target decreased to US$2.85 Nov 25
Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020) Nov 12
Sizing Up Surgalign Sep 23
Independent Director Jeffrey Lightcap has left the company Sep 17
Chairman Stuart Simpson has left the company Sep 17
Surgalign Holdings: Insiders Are Buying Aug 28
Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation Aug 20
President recently bought US$1.0m worth of stock Aug 14
Surgalign Holdings: Pinocchio Has A Happy Ending Aug 10
Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020) Aug 08
Price target decreased to US$4.21 Aug 07
Surgalign Holdings: A Marketing Ploy Jun 29 Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index
Surgalign reports inducement grants under Nasdaq listing rule Jun 04
First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020) May 11
Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System May 11
Surgalign Holdings, Inc. (NasdaqGS:SRGA) acquired Medical Device Prototyping and Manufacturing Facility in San Diego. May 08
Independent Director has left the company May 08
VP, Chief Accounting Officer & Corporate Controller has left the company May 08
Full year 2020 earnings released: US$2.61 loss per share (vs US$2.91 loss in FY 2019) Mar 18 Surgalign Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020
Shirley Weis Not to Stand for Re-Election as Director of Surgalign Holdings, Inc. At 2021 Annual Meeting of Stockholders Mar 14
Have Insiders Been Buying Surgalign Holdings, Inc. (NASDAQ:SRGA) Shares? Mar 08
Price target lowered to US$5.00 Mar 08
Surgalign Holdings, Inc. to Report Q4, 2020 Results on Mar 11, 2021 Feb 26
Surgalign Holdings, Inc., Annual General Meeting, May 04, 2021 Feb 13
Surgalign Holdings Announces the Commercial Launch of ViBone® Moldable and the First Clinical Implantation Jan 13
Surgalign Holdings : Strong Upside Potential Jan 11
Surgalign Holdings, Inc. Appoints Pawel (Paul) Lewicki to Board of Directors Nov 24
Surgalign Holdings, Inc. and Aziyo Biologics, Inc. Announce Expanded Distribution Agreement Nov 18 Shareholder Returns SRGA.Q US Medical Equipment US Market 7D 16.1% -1.1% -2.2% 1Y -99.5% 10.1% 23.9%
See full shareholder returns
Return vs Market: SRGA.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility Is SRGA.Q's price volatile compared to industry and market? SRGA.Q volatility SRGA.Q Average Weekly Movement 40.5% Medical Equipment Industry Average Movement 7.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SRGA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: SRGA.Q's weekly volatility has increased from 28% to 40% over the past year.
About the Company Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. It offers products for thoracolumbar procedures, including Streamline TL spinal fixation system, a system for degenerative and complex spine procedures; and Streamline MIS spinal fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability.
Show more Surgalign Holdings, Inc. Fundamentals Summary How do Surgalign Holdings's earnings and revenue compare to its market cap? SRGA.Q fundamental statistics Market cap US$165.30k Earnings (TTM ) -US$50.49m Revenue (TTM ) US$78.12m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SRGA.Q income statement (TTM ) Revenue US$78.12m Cost of Revenue US$26.03m Gross Profit US$52.09m Other Expenses US$102.58m Earnings -US$50.49m
Last Reported Earnings
Mar 31, 2023
Earnings per share (EPS) -5.50 Gross Margin 66.68% Net Profit Margin -64.63% Debt/Equity Ratio -54.1%
How did SRGA.Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/10/04 17:06 End of Day Share Price 2023/10/02 00:00 Earnings 2023/03/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Surgalign Holdings, Inc. is covered by 14 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raymond Myers Benchmark Company Michael Gorman BTIG William Plovanic Canaccord Genuity
Show 11 more analysts